If you're trying to understand your options for high cholesterol or high lipids, including after several approaches haven't been enough, you're in the right place.
That's a fair reason to be here.
Hyperlipidemia: where each option sits in the evidence
This map shows statins, other LDL medicines, icosapent ethyl, eating patterns, plant sterols, other triglyceride medicines, and popular supplements as different kinds of decisions. A change on the lipid panel is not automatically the same as proven protection from heart attack, stroke, or death. Some options have that harder evidence. Others mainly show lipid change.
Use this map to understand the options and prepare better questions for your clinician. It isn't a guide to starting, stopping, or changing treatment on your own.
How to use this page
This is a landscape of what has been studied, not a prescription.
Medicines stay on the map. Lifestyle options are calibrated by what they were shown to do. Ordinary fish oil is not the same decision as prescription purified EPA.
Open a topic that matches your question. Check it. Move to the next.
Bring what you learn to a clinician rather than changing treatment on your own.
The evidence landscape
See the different roles these options play. Not a menu. A landscape.
- Hard cardiovascular outcomes Statins · Non-statin LDL medicines · Icosapent ethyl
- Eating and food tools Eating patterns, saturated fat, and soluble fiber · Plant sterols and stanols
- Other triglyceride medicines Fibrates and related options
- Popular supplements What was studied
A change on the lipid panel is not the same as proven protection from heart attack, stroke, or death. Keep that distinction in mind as you move through the map.
What are you trying to figure out?
Find your question.
These are common decisions people face with high cholesterol or high lipids. The evidence isn't the same kind for every option. Some pages are about heart attack, stroke, and death. Others are mainly about lipid-panel change.
Hard cardiovascular outcomes
Statins, non-statin LDL medicines, and icosapent ethyl have event evidence in the pathways studied. They are different decisions.
- Do statins prevent heart attacks and strokes? How low should my LDL go? A very large trial base shows that lowering LDL with a statin reduces major vascular events. Roughly, about a one-fifth relative reduction tracks with each 1 mmol/L of LDL lowering. Guidelines still disagree about risk tools and how low to aim.
- If I can't take a statin, what else has event evidence for LDL? Ezetimibe, PCSK9 inhibitors, and bempedoic acid also have event evidence in the pathways studied, especially as add-ons or when a statin isn't tolerated. Heart-attack and stroke benefit is clearer than a clean all-cause mortality story in the pooled package used here. That is a different decision from starting a statin, not a weaker version of the same decision.
- Is prescription EPA the same as fish oil? Icosapent ethyl is a purified EPA medicine studied at 4 g/day in people with elevated triglycerides already on a statin. In that setting it reduced ischemic events. Those results do not transfer to mixed EPA/DHA products, ordinary fish-oil capsules, algae oil, or fibrates.
Eating and food tools
Portfolio-style eating, saturated-fat reduction, soluble fiber, and plant sterols are related but not the same decisions.
- Does the Portfolio pattern work? Does cutting saturated fat prevent events? Does fiber lower LDL? Three lines stay separate. A Portfolio-style pattern can lower LDL a lot without a hard-event package from that pattern alone. Cutting saturated fat reduces combined cardiovascular events in the review used here, without clear mortality certainty. Soluble fiber alone can lower LDL without hard-outcome proof from that tool alone.
- Do plant sterols lower LDL, and is that the same as preventing events? Plant sterols and stanols lower LDL in a dose-response way in many food-tool trials. That's not the same as the full Portfolio pattern, and it's not proven event prevention on its own.
Other triglyceride medicines
Fibrates and related options can change triglycerides. They are not a second icosapent ethyl story.
Popular supplements
Lipid-panel signals for some products. Not proven event prevention, and not a replacement for indicated care.
Evidence consulted Open sources
The eleven-source library behind this map. Topic pages carry object-specific sources. This is not a citation for every sentence.
- 2026 ACC/AHA Guideline on the Management of Dyslipidemia (A1)
- 2025 ESC/EAS Focused Update on dyslipidaemias (A2)
- NICE NG238. Cardiovascular disease: risk assessment and reduction, including lipid modification (A3)
- Khan et al. PCSK9 inhibitors and ezetimibe network meta-analysis (BMJ, 2022) (B1)
- CTT Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol (Lancet, 2010) (C1)
- Chiavaroli et al. Portfolio Dietary Pattern meta-analysis (2018) (C2)
- Hooper et al. Reduction in saturated fat intake for cardiovascular disease (Cochrane, 2020) (C3)
- Ras et al. Plant sterols and stanols dose–response meta-analysis (2014) (C4)
- Sabatine et al. FOURIER (NEJM, 2017) (D1)
- Nissen et al. CLEAR Outcomes (NEJM, 2023) (D2)
- Bhatt et al. REDUCE-IT (NEJM, 2019) (D3)
Start with the question closest to yours.